Leading Cannabinoid Biotech Company Announces Use of Oral Care Product Line in Registration for Clinical Trials in Australia and New Zealand AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and...
Safety data from all patients show that KB103 was well tolerated with no adverse events reported Five out of six wounds treated with KB103 in the Phase 2 trial closed 100% during the trial The average time to complete 100% wound closure on KB103 treated wounds in...
ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, has discontinued the Phase 2 global study for its...
— Following the successful launch of Oxervate, the first-in-class recombinant human nerve growth factor (rhNGF) for treatment of neurotrophic keratitis (NK), Dompé embarks on a new clinical trial program to further investigate the relevance of treatment with...
TRCA-301E trial is the first, long-term, randomized, multicenter, blinded, placebo-controlled trial to evaluate the treatment of metabolic acidosis in patients with CKD Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of...
Email
Text